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Studying potential drug interactions involved
in the regulation of the Diaphanous-related
formins

Brittany E. Benson and Dr. Bradley J. Wallar
Student Summer Scholars Program 2008

Diaphanous-related formins
(DRFs) are a conserved family of
proteins that are involved in the
regulation of cellular shape, motility,
and cell division by regulating the
structure of the cellular “skeleton”
(cytoskeleton); any disruption of this
regulation can result in cell death.
Normally, the DRFs are kept in an
inactive state by the intramolecular
binding of two regions of the protein:
the Diaphanous Autoregulatory
Domain (DAD) and Diaphanous
Inhibitory Domain (DID). This
binding can be alleviated by various
naturally-occurring mechanisms and
proper regulation of the activity of
these proteins is vital to cell survival
because prolonged activation of DRFs
can result in cell death. In a recent
scan of 10,000 chemical compounds,
two compounds (I and II) were
identified to bind to the DID region
and activate DRFs indefinitely
resulting in the killing of breast and
colon cancer cells. In this study, we
intend to prove that these compounds
are actually alleviating DID-DAD
binding (the essential step in DRF
activation) by directly binding to DID.
In addition, the specific location on
DID that binds these compounds must
be elucidated. We have hypothesized
three amino acid residues that
contribute to the binding of these
compounds, have generated them
using site-directed mutagenesis, and
have evaluated their ability to bind
the compounds using fluorescence
anisotropy. Further experiments will
test how these DID mutations affect
the ability for these compounds to
directly bind to DID using isothermal
titration calorimetry. By
characterizing the DID-compound
bound structure, these studies will

allow for the design of new
compounds that could bind more
tightly to DID, thereby resulting in a
drug that could efficiently kill cancer
cells.
Introduction
The Diaphanous-related formins (DRFs)
are a conserved group of proteins found
in many species, including yeast, slime
mold, worms, fruit flies, humans, and
others (1). They are responsible for the
remodeling of the cytoskeleton by
regulating actin nucleation and
elongation through the interaction with
their conserved formin homology 2
(FH2) domain (1,2). As a result, they
are involved in any process that requires
modification of the cytoskeleton,
including cell division, cell migration,
cell shape, and trafficking of cellular
proteins.
Because these proteins control
such integral processes in the cell, their
tight regulation is a necessity for normal
cellular growth. Any disruption of the
DRF regulation results in cellular
abnormalities, and eventually, apoptosis
(cellular ‘suicide’). Normally, the
Diaphanous-related formins are
autoregulated by the binding of their Nterminal Diaphanous-inhibitory Domain
(DID) to the C-terminal Diaphanousautoregulatory Domain (DAD), creating
a closed, inactive state (3,4) (see Figure
1). In this conformation, the FH2
domain is unexposed and thus unable to
nucleate actin (3,5). Naturally occurring
mechanisms exist that can activate DRFs
through disrupting this binding and
creating an open, active state. These
signaling proteins, such as Rho
GTPases, can temporarily bind to
another domain, the GTPase binding
domain (GBD), displacing DAD from

DID and creating the open conformation
in which the FH2 domain is available to
nucleate actin and activate other cellular
processes (3,5,6) (see Figure 2).
In knowing that any disruption of
these naturally occurring regulatory
mechanisms can elicit cell death, our
collaborators at the Van Andel Research
Institute initiated a 10,000 compound
scan to search for compounds that may
bind to DRFs and specifically disrupt the
DID-DAD interactions, thereby creating
a permanent active state. Using a highthroughput approach to a fluorescence
anisotropy assay designed and optimized
by Dr. Brad Wallar at GVSU, they
discovered two compounds (I/II) that
theoretically can bind to DID and
subsequently have been shown to kill
breast and colon cancer cells (see Figure
3). The goal of our project was to prove
that those cells died as a result of these
compounds binding to DID and upregulating DRFs by creating a
permanent open, active state.
Furthermore, we have planned to
elucidate the mechanism of this binding.
In order to explain the binding of
compounds I/II to DRFs (specifically
mDia2), we considered a known
structure of a similar DRF protein, as
well as predictions based on molecular
docking studies (computer modeling).
From these data, we have hypothesized
three residues (arginine-230,
isoleucine-276 and glutamine-322)
within the DID domain contribute to the
binding of compounds I/II. This project
was aimed at determining the
importance of these residues in DIDDAD binding and for compounds I/II to
bind to DID, as well as how strongly
these compounds bind to DID. In order
to accomplish this aim, we have made
mutations of these amino acid residues
(arginine-230 to a leucine,

isoleucine-276 to an aspartate and
glutamine-322 to a leucine). These
mutations change the polarity of each
residue and thus affect its ability to
hydrogen bond or interact with residues
of similar chemical properties. If these
residues are indeed involved in DIDDAD or DID-compound binding, then
these mutations should result in a loss of
that binding.
Discovering compounds that can
bind to DID, alleviate DID-DAD
binding, and subsequently kill cancer
cells represents an opportunity to create
a new chemotherapeutic drug. Many
current chemotherapeutic drugs, such as
Paclitaxel (commonly known as Taxol)
work by targeting the cytoskeleton,
binding directly to microtubules and
stabilizing them, preventing their
depolymerization and leading to mitotic
arrest (7). These compounds act
similarly to Taxol, but instead target the
proteins that regulate the cytoskeleton
rather than directly targeting the
cytoskeleton. While Taxol has been an
effective chemotherapeutic treatment, it
also exhibits side effects and tumor cell
resistance, and so it is now important to
identify other compounds that can
disrupt cytoskeletal function.
Materials and Methods
Mutagenesis and
Transformation: Plasmid DNA of the
mutants R230L, Q322L, I276D and wild
type GST-mDia2 (47-396) were
obtained using the Quikchange II XL
mutagenesis kit (Stratagene), and were
sent to the University of Michigan for
sequence verification. For protein
production, these plasmids were then
transformed into 50μL of competent
Rosetta 2 (DE3) cells. These cells were
incubated for 30 minutes on ice, heat

shocked at 42˚C for 30 seconds and then
incubated on ice for an additional 2
minutes. 200μL of SOC medium was
added and the cells were incubated at
37˚C while gently shaking for 20
minutes. Samples were then plated on
LB-ampicillin (100μg/mL)- 25μg/mL
chloramphenicol plates and grown up
overnight at 37˚C.
Expression and Purification of
Protein: One colony from each plate was
added to 50mL of LB media inoculated
with 100μg/mL ampicillin and 25μg/mL
chloramphenicol, which was gently
shaken overnight at 37˚C. These
cultures were then diluted into 1L LB
broth and 100μg/mL ampicillin,
25μg/mL chloramphenicol and shaken at
37˚C until the OD600 reached 0.6-0.8,
then incubated at 16˚C for 30 minutes
and induced with 1mM isopropyl-β-Dthiogalactopyranoside (IPTG) overnight
at 16˚C. Cells were lysed with lysis
buffer (25mM Tris-Cl, pH 7.5, 100mM
NaCl and 10mM MgCl2, HALT-Pierce
Protease Inhibitors, 50U DNase I and
2mM DTT), sonicated (4 x 15 seconds)
and centrifuged at 15,000 rpm for 30
minutes at 4˚C. Glutathione-agarose
beads were then added to the supernatant
(cell-free extract), incubated at 4˚C for 1
hour then washed 4 x 50mL with a wash
buffer of 200mL TMN (25mM Tris-Cl,
pH 7.5, 10mM MgCl2, 100mM NaCl)
with 0.1g DTT. Protein was eluted from
these beads using elution buffer (100mM
Tris-HCl, pH 8.0, 20mM reduced
glutathione, and 10mM DTT) and
concentrated to ~3mL using Amicon
Biomax 10 kDa cutoff filters,
centrifuging at 3,000 rpm and 4˚C.
Aliquots from throughout the
purification process were run on an
SDS-PAGE gel to verify the purity of
the final protein. Concentration was
determined by measuring absorbance at

280 nm and applying the theoretical
extinction coefficient of 51,490 M-1cm-1.
Fluorescence Anisotropy:
Binding studies were completed at 25ºC
using fluorescence anisotropy and were
completed on a Photon Technologies
Inc. model QM-7/2003 SE fluorometer
with polarization filters. All anisotropy
experiments consisted of purified GSTmDia2 (47-396) protein (DID)
sequentially added to a 10nM solution of
wild-type DAD peptide, diluted in TMN
buffer, pH 7.5. The fraction of DAD
peptide bound was determined by
defining the largest anisotropy change as
100% bound and comparing all other
anisotropy data to that value. The
concentration of free DID was also
determined by subtracting the total
concentration of bound DID (calculated
from the fraction bound) from the total
concentration of DID. The fraction
bound data versus the concentration of
free DID protein was plotted and fitted
using GraphPad Prism (see Figure 4).
Results
R230, Q322 and I276 are Important to
DID-DAD Binding – While it is known
that the DID and DAD domains bind to
each other in order to autoregulate the
nucleation of actin, the contribution of
all of the specific amino acid residues is
not fully understood. An important step
in our project was to first prove that
these residues are indeed important in
DID-DAD binding. By determining
this, we are able to give further evidence
that the binding of compounds I or II to
these residues will result in alleviation of
the DID-DAD interaction. Binding
curves generated from data obtained
from fluorescence anisotropy have
shown that the mutations R230L and

Q322L resulted in lower binding affinity
between DID and DAD, with
dissociation constants (KD) of 2406 nM
and 1380 nM, respectively, compared to
a KD of 285.9 nM for wild type DID.
The mutation I276D resulted in a KD
greater than 20 μM (20,000 nM), which
suggests complete lack of binding.
From these data, we now know that
these three residues (R230, Q322 and
I276) are important to DID-DAD
binding and are likely to bind to the
compounds I/II. As a result, an active
state of the DRF and eventual cell death
will result if these residues are unable to
bind to DAD as a result of mutation or
binding to a different compound.
Discussion
Discovering compounds that are able to
bind to and affect the regulation of DRFs
represents a novel advancement in
modern chemotherapeutic drugs. While
current drugs that bind directly to the
cytoskeleton are effective, they do
exhibit side effects and eventual tumor
cell resistance. Creating a new drug that
attacks the cell in an entirely different
way will allow us to overcome these
obstacles and possibly create an even
more effective treatment. Furthermore,
determining the mechanism for these
compounds binding to DRFs will allow
us design compounds that are even more
potent in the future
By using fluorescence
anisotropy, we will soon be able to
determine whether or not compounds I/II
are able to displace DAD from DID.
These experiments will involve titrating
DID into DAD to a point just before
saturation, and then adding either
compound I or II sequentially to observe
the results. When normal binding
occurs, anisotropy should increase, but

the addition of these compounds should
result in a decrease in anisotropy as a
result of DAD peptide becoming free in
solution and gaining the ability to rotate
freely. Anisotropy is a measure of the
loss of motion, therefore freely rotating
DAD peptide should result in a decrease
in anisotropy because of an increase in
motion.
Assuming these anisotropy
experiments are successful, we will then
move onto using isothermal titration
calorimetry (ITC) (use of this machine
provided to us by Dr. Nick Duesberry of
the Van Andel Research Institute) to
analyze direct binding between DID and
compounds I/II. Because we are unable
to attach a fluorophore to either of these
compounds, fluorescence anisotropy is
unable to monitor this direct binding to
DID and determine binding constants for
each. Knowing these binding constants
will enable us to measure the strength of
these interactions, and allow us to
compare these values to future
compounds that we may study. The
higher the affinity (stronger binding), the
more potent and effective these
compounds will be.
While much advancement in the
knowledge of DRFs (specifically mDia1
and mDia2) has been made recently,
much is still not known. This project
has enabled us to further determine
specific residues important to DID-DAD
binding in mDia2, helping to better
understand the mechanism of their
autoregulation. Their naturally
occurring autoregulatory mechanism is
somewhat understood, but no synthetic
chemical compound has been shown to
artificially regulate these proteins. If we
are able to prove that the cell death
experienced with the addition of these
compounds is due to their binding to the
DID region of DRFs, as well as

determine the mechanism of this
binding, we hope to use this information
to eventually construct new compounds
that will strongly bind to DID, thus
creating a more potent anti-cancer drug.
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Figure 1. Domain structure of a Diaphanous-related forming (mDia2). DRFs consist
of multiple domains that each contribute to the activity and regulation of these proteins.
The known domains include G or GBD (GTPase-binding domain), FH1 (Formin
homology 1 domain), DD (Dimerization domain), DID (Diaphanous inhibitory domain),
FH2 (Formin homology 2 domain), CC (Coiled coil region), and DAD (Diaphanous
autoregulatory domain).

Figure 2. Autoregulation of the Diaphanous-related formins. (A) Naturally occurring
mechanisms exist to regulate the activation of DRFs, such as the binding of Rho-GTPases
to the GBD, disrupting the DID/DAD binding and activating the DRF and leading to cell
movement and cell division. (B) We have proposed that compounds I/II work much in
the same manner, binding to the DID, but eventually causing cell death through
prolonged activation.
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Figure 3. Structure of compounds I/II. (A) After a 10,000 compound scan, these
two compounds were hypothesized to bind to mDia2 and in turn alleviate DID/DAD
binding, thus activating this protein. (B) Three residues: arginine-230 (R230),
glutamine-322 (Q322), and isoleucine-276 (I276) were then hypothesized to
contribute to DID-Compound binding. Based on a known structure of mDia1 (7), this
is a proposed model of our protein interacting with Compound II. There is no known
structure of this complex.
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Figure 4. Fluorescence anisotropy of the DID-DAD interaction. The above curves
were generated by the titration of wild type or mutant DID protein to fluorescent DAD
peptide. The mutant I276D has been left off of these curves because no significant
binding was detected with this mutant. (A) Raw data were generated for fluorescence
anisotropy and plotted using GraphPad Prism. Anisotropy change was determined by
subtracting the initial anisotropy from the value obtained at each titration of DID. As can
be seen, anisotropy grows in magnitude with increasing concentrations of DID, indicating
DID-DAD binding is occurring. (B) Anisotropy binding curves were generated by
obtaining the fraction of DAD peptide bound to DID and plotting that versus the free
DID concentration using GraphPad Prism.

